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A novel inclusion complex of the propiconazole nitrate (NO3PCZ) with b-cyclodextrin (b-CD) was prepared
by treatment of propiconazole (PCZ) with an acidic nitrating agent. The formation of NO3PCZ and its
inclusion complex with b-CD has been studied by NMR, ESI–MS, TGA, DSC methods. Using the undecoupled
signal in the HMBC correlation spectra, almost identical coupling constants of CH from trizolic ring of PCZ
and NO3PCZ compounds (
1J(HC)3¼207 Hz, 1J(CH)5¼214 Hz, for PCZ; 1J(HC)3¼208 Hz and 1J(CH)5¼
215 Hz, for NO3PCZ) were determined, conﬁrming that the geometry of the heterocyclic skeleton is identical
in both the forms. The 1:1 stoichiometry of the complex was determined by ESI–MS and was conﬁrmed
using Scott’s equation in DMSO and Higuchi and Connors equation in water. The solubility curve obtained
for NO3PCZ in presence of b-CD in distilled water was constructed, resulting in a solubility diagram of AL
type. Solubility of NO3PCZ in water was determined by DLS studies. The results showed that NO3PCZ was
encapsulated within the b-CD cavity with a binding constant of 330 M-1 in DMSO and 975 M-1 in water.
Preliminary pharmacological studies showed higher antifungal activities for NO3PCZ and its inclusion
complex, compared with its PCZ analog. The acute toxicity of the complex is smaller than the pure or
modiﬁed drug, recommending the inclusion complex as future promising therapeutic agents.
& 2011 Elsevier B.V. All rights reserved.1. Introduction
Over the past two decades, the incidence and diversity of fungal
infections has grown in relation with an increasing number of
immunocompromised patients and unfortunately, the attributable
mortality rate of fungal infections remains high [1]. Even the recent
studies, performed both in U.S. and Europe, have emphasized the
increasing incidence of nosocomial fungal infections, underlining at
the same time the high mortality rate which can attain 40–70% [2–5].
This increase in fungal infection intensiﬁed the research for new, safer,
and more efﬁcient agents [1,4–6]. The approval of the triazoles in the
early 1990swas amajor progress in the ability to safely and effectively
treat local and systemic fungal infections [1,5–9].
In addition, the increasing use of antifungal agents has led to
the development of resistance to the currently available antifun-
gals and it remains a continuous interest for developing new anti
fungal agents or reducing the dosage with decreased resistance
[10–14]. In this context, complexation of drugs with cyclodextrins
offers the possibility to improve their aqueous solubility withoutll rights reserved.
in Bionanoconjugates, ‘‘Petru
Aleea Grigore Ghica-Voda,changing their original structures and may allow a homogeneous
delivery systems of drugs, increasing their bioavailability [15–21].
Cyclodextrins are cyclic oligosaccaharides, that can form water-
soluble inclusion complexes with small molecules and portions of
large compounds and they have low toxicities in animals and
humans [16,22,23].
The emphasis of this work is to synthesize the inclusion
complex of propiconazole nitrate (NO3PCZ) with b-cyclodextrin
(b-CD) and, to study its properties, in order to test an improved
homogenous delivery system of propiconazole nitrate, as a means
of increasing its bioavailability. The structures of the propicona-
zole nitrate and its inclusion complex were demonstrated by
MS–ESI and 1H NMR studies. The propiconazole nitrate and its
inclusion complex were characterized by solubility studies and
TGA-DSC measurements. Finally, a preliminary investigation of
antifungal activity against 56 fungal strains is presented.2. Materials and methods
2.1. Materials
b-Cyclodextrin (b-CD) was purchased from Cyclolab (code CY-
2001), propiconazole (PCZ) (analytical standard), DMSO (Z99.9%),
Fig. 1. Propiconazole nitrate etalon curve in water.
N. Marangoci et al. / Results in Pharma Sciences 1 (2011) 27–3728ethanol (for HPLC) and methanol (for HPLC) from Sigma-Aldrich and
they were used as given. Double distilled water was used throughout
the study.
2.2. Preparation of the propiconazole nitrate
Propiconazole nitrate (NO3PCZ) (Scheme 1) was prepared as
already described [24] by the treatment of propiconazole (PCZ)
with acidic nitrating agent (mixture of nitric and acetic acid in a
1:3 molar ratio) in chloroform, at room temperature for 18 h. The
yellowish-white powder of propiconazole nitrate (NO3PCZ) was
further puriﬁed by maintaining the sample to a pressure of about
5103 Pa at a temperature of about 50 1C for approximately
5 h, in order to remove any volatile chemicals.
Propiconazole nitrate is a crystalline, white powder, without
odor; which presents high solubility in ethanol, methanol, organic
solvents (DMSO) and very low solubility in water. The melting
point for propiconazole nitrate is around 133.5 1C, according with
Valica’s results [25].
2.3. Preparation of the solid inclusion complex
The inclusion complex was prepared by freeze-drying method.
A solution of water and methanol (1/1 v/v) containing NO3PCZ and
b-CD in a 1:1 molar ratio was frozen by immersimg it in liquid
nitrogen and freeze-dried in a Martin Christ, ALPHA 1-2LD Freeze-
Dryer. The solution was obtained by dissolving 4.349104 mol
NO3PCZ and 4.349104 mol b-cyclodextrin in 25mL water/metha-
nol mixture (1/1 v/v) and stirring it at room temperature for 12 h.
2.4. Preparation of the physical mixture
The physical mixture was performed by mixing the powders in
a 1:1 molar ratio of drug and CD in a ceramic mortar.
Estimation method for the solubility of propiconazole
nitrate (NO3PCZ) in water: The solubility in water of NO3PCZ
was carried out based on DLS measurements. Water solutions of
different concentrations of NO3PCZ (6.56109–4104 M)
were shaken for 24 h at room temperature. The solutions were
analyzed by means of the DLS method, giving information on zeta
potential values and sizes of particles or aggregates or colloids
(Table 1). The solution with the modulus of zeta potential (z)
higher than 30 mV will give the solubility of propiconazole nitrate
in water.
2.5. Phase solubility studies
Phase solubility studies were carried out according to the
Higuchi and Connors method [26]. b-CD solutions of different
concentrations (3.3104–16.2103 M) were added to a super-
saturated solution of propiconazole nitrate (NO3PCZ) and shaken at
room temperature (2271 1C) for 24 h. After reaching equilibrium,Table 1
Zeta potential and particle sizes in water at different concentrations of NO3PCZ.
NO3PCZ
(M)
Average
diameter
(nm)
d10
(nm)
d50
(nm)
d90
(nm)
Zeta
potential
(mV)
Mobility
(cm2/V s)
8.23E04 854.1 716.4 815.9 967.2 0.59 4.64E06
4.11E04 430.2 390.8 422.3 461.8 6.97 5.44E05
2.06E04 665.9 494.2 603.7 808.1 2.8 1.83E05
1.03E04 523 366.3 459.2 663.2 2.8 2.19E05
2.10E06 452.2 316 395.5 576.4 6.97 5.44E05
8.24E08 212.8 179.2 202.8 249.6 5.75 4.49E05
4.10E08 179 133.2 155 224.1 41.89 3.27E04the solutions were ﬁltered (0.45 mm, nylon disk ﬁlter). All samples
were analyzed in triplicate. The absorbance of solutions containing
different mole fractions of the drug and b-CD was measured by UV
at 270 nm and the concentration of NO3PCZ in each solution was
determined with reference to a suitable constructed standard curve
(Fig. 1).
The apparent stability constant was calculated from the initial
straight portion of the phase solubility diagram using [26]
K1 : 1¼ Slope
S0ð1SlopeÞ
ð1Þ
where S0 is the solubility of NO3PCZ in the absence of b-CD,
slope is the slope of the experimental phase solubility diagram for
b-CD–NO3PCZ.
Nuclear magnetic resonance (NMR): The NMR spectra have
been recorded on a Bruker Avance DRX 400 spectrometer operating
at 400.1 MHz for 1H and 100.6 for 13C nuclei. The proton chemical
shifts are reported both in Hz and ppm, relative to the solvent
residual peak as internal standard (DMSO, 1H, 2.51 ppm/1005.13 Hz;
13C, 39.41 ppm). Stock solutions of 0.01 M propiconazole nitrate and
0.01 M b-CD in DMSO were mixed as required. NMR spectra were
recorded for a series of mixtures. Molar ratio of [NO3PCZ]/[b-CD]
varied from 0:1 to 1:1.
UVmeasurementswere performed on a Analytik Jena Specord
200 Spectrophotometer.
Dynamic light scattering (DLS): The hydrodynamic diameter,
polydispersity and zeta potential of the particles were examined
using the Delsa Nano Submicron Particle Size Analyzer (Beckman
Colter) that use photon correlation spectroscopy (PCS), which
determines particle size by measuring the rate of ﬂuctuations in
laser light intensity scattered by particles as they diffuse through
a ﬂuid, for size analysis measurements and electrophoretic light
scattering (ELS), which in turn determines electrophoretic move-
ment of charged particles under an applied electric ﬁeld, for zeta
potential determination. Electrophoretic light scattering is the
method most popularly used to determine the velocity of the
particles suspended in a ﬂuid medium under an applied electric
ﬁeld. This analyzer determines the particle size of suspensions in
a range from 0.6 nm to 7 mm.
Mass spectrometry results were obtained using an Agilent
6520 Series Accurate-Mass Quadrupole Time-of-Flight (Q-TOF)
LC/MS. The solutions were introduced into the electrospray ion
source (ESI) via a syringe pump at a ﬂow-rate of 0.2 mL/min. After
optimization of the Q/TOF MS parameters, they were set as
Scheme 1. Treatment of 1,2,4-triazoles with acidic nitrating agents (a) and
proposed structure of NO3PCZ (b).
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(N2) ﬂow rate 7.0 L/min; drying gas temperature 325 1C; nebuli-
zer pressure 35 psig, capillary voltage 4000 V; fragmentation
voltage 200 V; the full-scan mass spectra of the investigated
compounds were acquired in the range m/z 100–3000. The mass
scale was calibrated using the standard calibration procedure and
compounds provided by the manufacturer.
In the MS/MS experiment, nitrogen was used as collision gas,
the mass selected monoisotopic parent ions were isolated in the
quadrupole with an isolation width of 1.3m/z and fragmented by
collision with N2 gas. The relative CID energies for the dissociation
of samples in the positive ion mode were 20, 30 and 40 eV. Data
were collected and processed using MassHunter Workstation
software.
Thermogravimetric experiments were conducted on a Mettler
TGA/SDTA 851e device. 3–3.5 mg of each sample was heated in
Al2O3 crucibles with lids. The samples were heated from 25 to
700 1C at a rate of 10 1C/min. Nitrogen atmosphere was used, at a
ﬂow rate of 5 mL/min.
Differential scanning calorimetry (DSC) experiments were
conducted on a Mettler DSC 1 STARe device. 3–3.5 mg of each
sample was heated in aluminum crucibles with pressed lids. The
samples were heated at a rate of 10 1C/min in nitrogen atmo-
sphere at a ﬂow rate of 150 mL/min.
2.6. Pharmacological studies
2.6.1. Preliminary in vitro antifungal activity studies
A total number of 56 Candida albicans strains collected
between 2007 and 2009 from bloodstream infections in three
tertiary hospitals from Romania have been assessed. The strains
were isolated from blood cultures using BacT/ALERT bottles
(bioMe´rieux, Marcy l’Etoile, France) and subsequently identiﬁed
using standard laboratory procedures including morphological
and biochemical methods.
Pure PCZ, NO3PCZ and b-CD–NO3PCZ inclusion complexes
were assessed at following ﬁnal concentrations of active sub-
stances (mg/L): 0.0156; 0.0312; 0.0625; 0.125; 0.250; 0.500; 1.00;
2.00; 4.00; 8.00; 16.00; 32.00; 64.00; 128.00. For PCZ and NO3PCZ,
DMSO was used as solvent, while the b-CD–NO3PCZ complex was
dissolved in pure sterile water.
In vitro susceptibility was assessed accordingly to the guide-
lines of AFST-EUCAST E. Def. 7.1 [27]. The tests were performed
in RPMI-1640 medium buffered with MOPS and supplemented
with 2% glucose. Microplates were prepared and stored frozen
at 20 1C until their use (no more than one month). The ﬁnal size
of inoculum was adjusted to 105 CFU/mL. MICs (minimal inhibi-
tory concentrations) were determined spectrophotometrically
after 24 h of incubation at 36 1C, using the MR-96A microplate
reader (Mindray, China). The MIC endpoint was deﬁned as 50% or
more reduction in growth compared to that in the drug-free well.
Two reference strains, Candida krusei ATCC 6258 and C. para-
psilosis ATCC 22019, were included in each set of determinations
to assure the quality of results. After acquirement of the MIC
values, the following parameters were calculated using speciﬁc
statistical software: MIC50 (the concentration of drug capable to
inhibit 50% of strains), MIC90 (the concentration of drug capable
to inhibit 90% of strains) and GM (geometric mean). The MIC50
and MIC90 of the tested isolates were determined because a
number of strains Z5 and Z10, respectively, were available [28].
2.7. Acute toxicity studies
Acute toxicity studies were performed on laboratory mice—
nulliparous and non-pregnant healthy young females with age
between 8 and 12 weeks, and weight around 2070.2 g. Theanimals were housed individually, respecting the same micro-
climate (temperature around 22173 1C, the relative humidity
55% and an alternation of 12 h artiﬁcial light, 12 h darkness) and
feeding conditions. The animals were randomly selected, marked
to permit individual identiﬁcation, and kept in their cages for at
least 5 days prior to dosing, in order to allow the acclimatization
to the laboratory conditions. Two suspensions of 35 and 17.5 mg/
mL of NO3PCZ in water and two solutions of 24 and 12 mg/mL of
b-CD–NO3PCZ inclusion complex in water were prepared (accord-
ing to the solubility studies, the solubility of NO3PCZ and b-CD–
NO3PCZ in water are 4.1108 and 16103 mol/L, respec-
tively). The administration of the pure and complexed NO3PCZ
was made, affording doses of 0.172, 0.086 for NO3PCZ and 0.035,
0.017 for b-CD–NO3PCZ mmol/100 g body [21,29]. The dose
volume (2 mL) was administered by gavage using a stomach tube.
The experiments were performed on Wistar SD1 NRM1 White/
C57Bi6 mice, offered by the Cantacuzino Institute, Bucharest
(Romania).
The acute toxicity (LD50) was established using the Dixon and
Mood method (OECD no. 19, 2000; OECD no. 24, 2000).3. Results and discussions
3.1. Propiconazole nitrate
Propiconazole nitrate was obtained by treating propiconazole
with a mixture of nitric acid and acetic acid in chloroform [24],
when it does not act as a nitration agent because of the low
reactivity of the ring carbon atoms with respect to electrophiles.
In these conditions, an additional activation of the triazole rings
when they are protanated in acids is produced [14,30,31]
(Scheme 1). The nitration of 1,2,4 triazole by HNO3/CH3COOH
takes place only at 8 to 10 1C [31].3.2. NMR spectroscopy
1H NMR spectrum of propiconazole nitrate (Fig. 2) presents the
characteristic signals of propiconazole, showing two diastereomers
and the chemical shifts are in agreement with those previously
published [26]. The observed differences between our data and
those previously published are due to different solvent induced
chemical shifts (CDCl3 vs. DMSO). For this study we choose to record
Fig. 2. 1H NMR (DMSO) of propiconazole nitrate.
Table 2
1H chemical shift (d ppm) of propiconazole and propiconazole nitrate.
Propiconazole Propiconazole nitrate
Major isomer
d ppm
(multiplicity)
Minor isomer
d ppm
(multiplicity)
Major isomer
d ppm
(multiplicity)
Minor isomer
d ppm
(multiplicity)
H3 7.87 (s) 7.83 (s) 8.02 (s) 7.97 (s)
H5 8.41 (s) 8.40 (s) 8.60 (s) 8.58 (s)
H17 7.65 (d) 7.63 (d) 7.66 (d) 7.65 (d)
H19 7.41 (dd) 7.38 (dd) 7.43 (dd) 7.39 (dd)
H20 7.49 (d) 7.45 (d) 7.50 (d) 7.46 (d)
H10 3.82–3.96 (m) 3.35 (t) 3.83–3.98 (m) 3.35 (t)
3.19–3.28 (m) 4.10 (dd) 3.19–3.31 (m) 4.10 (dd)
H9 3.82–3.96 (m) 3.82–3.96 (m) 3.83–3.98 (m) 3.83–3.98 (m)
H6 4.66–4.82 (m) 4.66–4.82 (m) 4.70–4.83 (m) 4.70–4.83 (m)
H12 1.15–1.44 (m) 1.15–1.44 (m) 1.15–1.44 (m) 1.15–1.44 (m)
H13 1.15–1.44 (m) 1.15–1.44 (m) 1.15–1.44 (m) 1.15–1.44 (m)
H14 0.85 (t) 0.83 (t) 0.87 (t) 0.85(t)
Table 3
13C Chemical shifts of propiconazole and propiconazole nitrate.
Propiconazole Propiconazole nitrate
Major isomer
d ppm
Minor isomer
d ppm
Major isomer
d ppm
Minor isomer
d ppm
C3 150.62 150.71 148.58 148.75
C5 145.28 145.14 144.79 144.66
C6 53.33 53.40 53.80 53.90
C7 106.33 106.32 106.15 106.15
C9 76.16 77.22 76.23 77.39
C10 69.43 69.50 69.48 69.59
C12 34.07 34.30 34.12 34.36
C13 18.33 18.42 18.32 18.43
C14 13.74 13.69 13.77 13.73
C15 135.48 136.14 135.23 135.92
C16 132.41 132.32 132.44 132.36
C17 130.46 130.24 130.5 130.35
C18 134.25 134.08 134.43 134.26
C19 127.10 126.96 127.23 127.10
C20 129.84 129.57 129.95 129.65
Fig. 3. DEPT135 spectrum of propiconazole nitrate.
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soluble in this solvent.
A remarkable deshielding of H3 and H5 of pure propiconazole
in propiconazole nitrate shows the formation of the ammonium
ion in the triazole rings (Scheme 1 and Table 2). 13C peak values
are presented in Table 3.
A previous study [26] reported ‘‘wrong side’’ for the signals C3
and C5 in propiconazole in the J modulated spectrum. We recordedthe DEPT135 J modulated spectrum for the propiconazole nitrate
with our standard Bruker TopSpin 1.3PL10 parameters, in spite of
the fact that we have conﬁrmed very large C–H couplings and we
did not notice any abnormalities in the J modulated spectrum
(Fig. 3). The signals CH-3 and CH-5 were reported earlier [26] as
unusually appearing on the same side with CH2 groups. As we did
not notice this abnormality in our spectra, we may assume that the
situation may be due to the speciﬁc parameter set used by those
authors. Using the undecoupled signal in the HMBC correlation
spectra we measured almost identical coupling constant, i.e.
1J(HC)3¼207 Hz, 1J(CH)5¼214 Hz in the case of propiconazole and
1J(HC)3¼208 Hz and 1J(CH)5¼215 Hz in the case of propiconazole
nitrate. These values conﬁrm the fact that the geometry of the
heterocyclic skeleton is identical in the two forms.
1H NMR spectra of b-CD as a function of propiconazole nitrate
concentration are shown in Fig. 4 (in Hz). From this ﬁgure one can
observe shifted NMR signals for H3 and H5 of propiconazole nitrate
(region a) and H3, H5, H6 of cyclodextrin (region f) while all the other
peaks of both cyclodextrin and propiconazole nitrate remain almost
unchanged, indicating an inclusion phenomenon of the drug into
cyclodextrin cavity. Analyzing the chemical structure of propicona-
zole nitrate (Scheme 1) we can suppose the formation of three types
of inclusion complexes, depending on part of propiconazole nitrate:
dichlorobenzene part, alcohol part and protonated 1,2,4-triazole part
which could be included alternatively in b-CD cavity with a more or
less probability. A remarkable downﬁeld shift of H3 and H5 of pure
propiconazole nitrate in complex shows that the propiconazole
nitrate penetrates b-CD cavity (perturbing its H3, H5, H6 protons)
with a more pronounced probability to form inclusion complex when
the triazolic ring penetrates the cavity of the b-CD. It should be noted
that this remark was made by our group [19,21] and the other groups
[32,33] studying the inclusion of protonated sulconazole and mico-
nazole forms into b-CD cavity. Since the C–H bonds of positions 3,
5 and 6 of glucopyranosyl unit are toward the b-CD cavity, shielding
effects due to the protonated triazole ring should inﬂuence the
chemical shifts of the host protons. The upﬁeld-shifted signals of
H3, H5, H6 of pure b-CD in complex suggested that the majority of
those protons should not be exactly in the same plane of the triazolic
ring. In addition, those shifted peaks are undistinguishable between
the bond and the free state of b-CD. For this reason, for further studies
we consider the shift of H3 of b-CD, only. On the other hand, the H2
and H4 protons of b-CD have no signiﬁcant changes in the chemical
shift, demonstrating that these protons do not interact directly with
drug because they are exposed to bulk environments.
3.3. Electrospray ionization–mass spectrometry (ESI–MS)
The mass spectrometry analysis of various drugs has become
important because of the increased need to develop new and
better drug formulations. ESI–MS is a relatively soft ionization
Fig. 4. (1) Full 1H NMR spectra (Hz) as a function of molar ratio of b-CD/NO3PCZ; (2) partial 1H NMR (Hz) showing upﬁeld shift of H3, H5, H6 protons from b-CD with the
increasing amount of NO3PCZ, but H2, H4 relatively unchanged; (3) an enlargement of selected region demonstrating shift for H3 and H5 protons of NO3PCZ while its
amount is increasing; b-CD/NO3PCZ molar ratio: 19.0 (A); 13.0 (B); 9 (C); 4.0 (D); 1.5 (E); 1.0 (F); 1H Peaks in each region (a–e) are as follows: H3 and H5 of NO3PCZ (a);
aromatic NO3PCZ (b); H from OH and H1 of b-CD and H6, H9, H10 of NO3PCZ (c,d,e); H3, H5, H6 of b-CD (f); H2, H4 of b-CD and H10 of NO3PCZ (g); H12, H13, H14 of NO3PCZ (h).
Fig. 5. Full scan positive ESI mass spectrum of PCZ in methanol solution.
N. Marangoci et al. / Results in Pharma Sciences 1 (2011) 27–37 31technique used for analysis of biomolecules, becoming very
effective methods for determination of molecular association of
non-covalent bonding [34,35]. The ability of ESI to maintain the
non-covalent structure of a biomolecule in its transition from the
liquid to gas phase has provided a number of opportunities to
study the formation of inclusion complexes of cyclodextrins with
different organic molecules and several drugs [36–38].
Before the inclusion complex was investigated by ESI–MS, the
b-CD and drug molecules: propiconazole (PCZ) and propiconazolenitrate (NO3PCZ) were analyzed individually to check their purity
in order to contrast the relative CID energies between b-CD and
its complex.
The formation of the molecular ion by ESI–MS occurs only in
positive mode and therefore only positive ions were analyzed. It is
most likely that the proton will be retained onto the nitrogen
atom of the 1,2,4-triazole heterocycle of PCZ molecule. The
ESI–MS spectrum for PCZ in methanol solutions is shown in
Fig. 5, and the zoom isotope peaks of PCZ isomers are also shown
N. Marangoci et al. / Results in Pharma Sciences 1 (2011) 27–3732as an inset in the ﬁgure. Speciﬁcally for PCZ molecules (mixture of
four stereoisomers) there is an observation that the isomers arise
at m/z 342 and 344. Besides the formation of the propiconazole
species one may observe the low intensity peaks at m/z 364 and
707, which can be attributed to sodium PCZ adduct and later to
the sodium adduct of the two associated PCZ molecule.
The ESI–MS analysis of NO3PCZ in water methanol mixture
(1:1 v/v) (Fig. 6) revealed the formation of proton charged propico-
nazole nitrate at m/z¼405, which conﬁrms that the nitration
reaction of PCZ was successfully carried out and can be observed
by this technique.
Fig. 7 shows ESI-MS spectrum of b-CD–NO3PCZ inclusion
complex in water methanol mixture (1:1 v/v), where the most
abundant peak at m/z 1157 corresponds to b-CD sodium adduct,Fig. 6. Full scan positive ESI mass spectrum of N
Fig. 7. Full scan positive ESI mass spectrum of b-CD–NO3PCZ
Fig. 8. Collision-induced dissociation (CID) spectruwhile a peak at 1199m/z can be attributed to NO3CD. The peak at
m/z 1540 corresponds to [b-CD–NO3PCZþHþ]þ which directly
conﬁrmed the 1:1 complex formation between b-CD and NO3PCZ.
In order to obtain information on the binding strength of the
non-covalent complex, MS/MS experiments on b-CD, PCZ, NO3PCZ
and their inclusion complexes were performed.
The tandemmass spectra in the positive ionmode for the PCZ ions
at the collision energy of 30 eV (Fig. 8) revealed a major peak at m/z
158 which can be attributed to C7H5Cl2 fragment from PCZ and the
other small peaks, resulting solely, from PCZ fragmentation (Fig. 9).
The tandem mass spectra in the positive ion mode for the
NO3PCZ ions at the collision energy of 30 eV are shown in Fig. 10.
The peaks resulting from NO3PCZ fragmentation are observed at
m/z 219, 259, 306 and 319, assigned to the structures from Fig. 11.O3PCZ in 1:1 v/v water–methanol solution.
inclusion complex in 1:1 v/v water–methanol solution.
m of the PCZ at the collision energy of 30 eV.
N. Marangoci et al. / Results in Pharma Sciences 1 (2011) 27–37 33A conﬁrmatory experiment of the formation of [b-CD–
NO3PCZþHþ]þ complex, made using different relative collision
energies (10–50 eV), put out its speciﬁc peak at m/z 1540 (Fig. 12).
The peak at m/z 1197 observed on MS spectrum in Fig. 13 is the
result of the PCZ molecule loss from the inclusion complex, by
dissociation process of propiconazol nitrate in electrospray
conditions and recombination of NO3 ion with b-CD. In addition,
the typical fragmentation of b-CD proceeds through scission of the
1,4-glycosydic bonds between glycoside units to yield linear frag-
ments with 162 Da (the mass of one glycoside unit) sequence.
Moreover, not only glycosidic bond cleavages are observed, but also
some special ions are detected, obtained from the degradation of
NO3PCZ molecules.
In conclusion, the fragmentation of b-CD–NO3PCZ inclusion
complex involves two distinct processes: a ﬁrst fragmentation
occurs by neutral loss of PCZ; the second fragmentation pathway
consists of b-CD dissociation by consecutive losses of one
glycosidic unit.
The 1:1 stoichiometry of the complex was determined by mass
spectroscopy and was conﬁrmed using Scott’s equation for NMR
applications obtained by modiﬁcation of Hildebrand–Benesi
equation [39,40]:
½b-CDi=Ddobs ¼ ½b-CDi=Ddcþ1=KaDdc ð2Þ
where [b-CD]i is the molar concentration of b-CD, Ddobs is the
observed chemical shift difference between H3 of pure b-CD and
H3 of b-CD at a given concentration, Ddc is the chemical shift
difference between H3 of pure b-CD and H3 of b-CD from a pure
sample of the complex. The plot for [b-CD]/Ddobs vs. [b-CD] gave aFig. 9. Possible fragments of PCZ.
Fig. 10. Collision-induced dissociation (CID) spectrulinear ﬁt (Fig. 13), conﬁrming 1:1 stoichiometry for the complex
and its intercept with the vertical axis allows to estimate Ka. The
binding constant was determined to be 330 M1 in good agree-
ment with the observed values of Ka in a 1:1 stoichiometry and is
most often between 50 and 2000 M1 and strongly affected by
the accuracy of the intercept [22,23,41].
3.4. DLS studies
3.4.1. Samples with zeta potential
The solutions of zeta potentials between 30 mV and
þ30 mV typically tend to aggregate. Determining the stability of
the sample, either to minimize aggregation for drug, the modulus
of zeta potential should be higher than 30 mV [42]. Zeta potential
of the solution with a concentration of about 4.1108 M
propiconazole nitrate (Table 1) due to the presence of cationic
groups demonstrated a high potential value of about þ42 mV,
ensuring a high-energy barrier that stabilizes the nanosuspension.
Finally, a concentration of about 4.1108 M propiconazole
nitrate in water was considered as the solubility of the drug.
3.4.2. Phase solubility studies
In Fig. 14 the solubility curve obtained for NO3PCZ in the
presence of b-CD in distilled water is shown. As it can be seen,
NO3PCZ solubility in water presents a linear growth; the resulting
linear curve can be classiﬁed, in general, as an AL type (linear
positive isotherm), as described in the literature [26]. Since the
slope of the diagram is less than 1 (0.404104) it was assumed
that the stoichiometry of each complex is 1:1 according to
Higuchi and Connors [26]. It should be noted that the solubility
of the propiconazole nitrate in the presence of b-cyclodextrin is
increasing up to 16 mM, when [b-CD]¼[NO3PCZ] and it reached
the limit of solubility of b-CD. The binding or association constant,
K1:1, of the complex in water was calculated from the corre-
spondent curve of Fig. 15 according to Eq. (1) and it was found to
be around 975 M1. In addition, the value is between 100 and
10,000 M1, which is typical to many CD–drug complexes
[22,23,41].
3.5. Thermogravimetric analysis
TGA curves from Fig. 15 and Table 4 are describing weight
losses of the pure components (propiconazole nitrate (NO3PCZ)
and b-cyclodextrin (b-CD)) and of their inclusion complex
obtained by the freeze-drying method.
Pure NO3PCZ has a ﬁrst stage of decomposition between 132
and 166 1C, reaching a weight loss of 16.50%, and this step ism of the NO3PCZ at the collision energy: 30 eV.
Fig. 11. Possible fragments of NO3PCZ.
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at 250 1C, the weight loss is increasing rapidly reaching 95% at
320 1C. b-CD loses water in the 50–104 1C interval and starts
degrading at about 260 1C. It can be seen from Fig. 16 and Table 4
that the thermostability of the guest molecule was increased,
from 132 to 152 1C, due to its inclusion in the cavity of cyclodex-
trin [19]. In conclusion, TGA analysis indicated inclusion complex
formation at the triazolic ring by increasing the thermostability of
the triazole ring of drug from 132 to 152 1C after complexation.
3.6. Differential scanning calorimetry (DSC)
DSC reveals some information on solid state interactions
between drug and cyclodextrin.
The DSC curves of the pure NO3PCZ and of the physical
mixture (3.5/3.5 w/w) (non-complexed components) exhibit two
melting peaks of different intensities at 126 and 137 1C, due to the
fact that the drug has a minor and a major isomer [44,45](Fig. 16). The loss of crystallized water from b-CD exhibits a
broad endothermic peak, both in pure b-CD and physical mixture,
around 110 1C. Analyzing the DSC curve of the inclusion complex
it can be observed that the two endothermic peaks of drug occur
in a single broad peak at 140 1C, with a small intensity, which can
be attributed to the formation of a new solid phase.
DSC curves indicated an inclusion process by the presence of a
much smaller and ﬂat melting peak in the curve of the complex,
compared to those of pure propiconazole nitrate [46,47].
3.7. Preliminary in vitro antifungal activity studies
Preliminary comparative data on antifungal activity of PCZ,
NO3PCZ and b-CD–NO3PCZ complex molecules are presented in
Table 5.
Overall, the antifungal activity of NO3PCZ and b-CD–NO3PCZ
was exhibited at very low concentrations of the active substance,
the values of MIC50 and MIC90 being 0.0156 and 0.0312 mg/L,
Fig. 13. Scott’s plot of the b-CD–NO3PCZ complex.
Fig. 14. Phase solubility diagram for the b-CD–NO3PCZ system.
Fig. 12. Collision-induced dissociation (CID) spectrum of the bCD–NO3PCZ at the collision energy: 10 and 40 eV.
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in vitro activity against Candida albicans strains (p40.05) and this
fact indicates a good availability of the drug in aqueous medium
by incorporating the drug into CD cavity. Also, the data showed in
Table 5 demonstrated that PCZ alone presented higher MICs than
its derivatives (NO3PCZ), this fact indicating a limited antifungal
effect of this parental triazole molecule. The results suggest that the
nitration of PCZ clearly improve its antifungal effect and NO3PCZ
may be a useful antifungal drug, but more pharmacological and
microbiological investigations are needed in order to establish its
activity spectrum, to prove its efﬁciency on animal models of
invasive fungal infections, to ﬁnd interpretative breakpoints for
in vitro susceptibility testing and to evaluate the pharmacokinetic
and pharmacodynamic aspects. Moreover, the formulation ofNO3PCZ, as inclusion complex with b-CD, is a promising aspect
which enables the parenteral administration of the drug.
3.8. Acute toxicity studies
The acute toxicity studies’ data showed that the acute toxicity
of the b-CD–NO3PCZ inclusion complex on comparing with the
free NO3PCZ, analyzed separately, is quite close. The LD50 for the
b-CD–NO3PCZ lyophilized complex is 280 mg/kg body weight and
the value of LD50 obtained for free NO3PCZ after oral adminis-
tration is 350 mg/kg body weight in mice, classifying the drug as a
class 2 substance (moderately hazardous), according to WHO
[48]. These toxicity values are quite similar to that of voriconazole
[49]—an approved antifungal drug for human usage [50].
Fig. 15. TGA curves of b-CD, NO3PCZ, b-CD–NO3PCZ inclusion complex.
Table 4
Decomposition results of NO3PCZ, b-CD and b-CD–NO3PCZ inclusion complex.
Code Degradation
step
Degradation temperature
(1C)
Weight
loss (%)
Residue
(%)
Initial
temperature
Final
temperature
NO3PPZ I 132.27 166.15 16.50 5.83
II 193.83 320.57 77.58
b-CD I 50.69 104.61 13.14 10.02
II 264.11 342.03 76.76
b-CD–
NO3PCZ
I 55.77 92.18 5.48 8.72
II 152.32 179.98 5.24
III 197.98 342.03 80.18
Fig. 16. DSC curves of b-CD (1); NO3PCZ (2); b-CD–NO3PCZ (3); physical mixture
of NO3PCZ and b-CD (4).
Table 5
Comparative antifungal activity of PCZ, NO3PCZ and b-CD–NO3PCZ complex
molecules against Candida albicans strains.
Tested molecules MIC (mg/L)
Range of concentrationsa MIC50 MIC90 GM
b-CD–NO3PCZ 0.0156–0.0625 0.0156 0.0312 0.0194
NO3PCZ 0.0156–0.0625 0.0156 0.0312 0.0198
PCZ 8–128 16 128 94.2370
a When yeast strains are sensitive.
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The NMR and ESI–MS studies prove the protonation of the
triazolic ring of the propiconazole when it is treated with a
mixture of nitric acid and acetic acid in chloroform. In this case,
the mixture of nitric acid and acetic acid does not act as anitration agent because of the low reactivity of the carbon atoms
of the triazolic ring.
The DEPT135 J modulated spectrum for the propiconazole
nitrate shows very large C–H couplings (1J(HC)3¼207 Hz,
1J(CH)5¼214 Hz in the case of propiconazole and 1J(HC)3¼208 Hz
and 1J(CH)5¼215 Hz in the case of propiconazol nitare), conﬁrm-
ing the fact that the geometry of the heterocyclic skeleton is
identical in those two forms. From 1H NMR a spectrum of
inclusion complex can be observed by shifted NMR signals for
H3 and H5 of propiconazole nitrate and H3, H5, H6 of cyclodextrin
while all the other peaks of both cyclodextrin and propiconazole
nitrate remain almost unchanged, indicating an inclusion phe-
nomenon of the drug into cyclodextrin cavity. Also, a remarkable
downﬁeld shift of H3 and H5 of the propiconazole nitrate in
complex shows that the propiconazole nitrate penetrates b-CD
cavity (perturbing its H3, H5, H6 protons) with a more pronounced
probability to form the inclusion complex when the triazolic ring
penetrates the cavity of b-CD.
The ESI–MS data and phase solubility studies show that b-CD–
NO3PCZ inclusion complex is formed in a molar ratio of 1:1 b-CD
and NO3PCZ. The water solubility of propiconazole nitrate
increased linearly (AL type) when the concentration of b-CD
increased. The binding or association constant, K1:1, was found
to be around 330 M1 in MSO and 975 M1 in water. Also, taking
into account antifungal potencies, low toxicities, synthetic acces-
sibilities and good pharmaceutical properties, b-CD–NO3PCZ
inclusion complex may be an excellent promising antifungal
agent and may lead to for further preclinical studies on its use
as topical antifungal drug candidates to manage oral candidiasis
and dermatomycosis.Acknowledgment
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